Oct. 21, 2002 — Low-flow cerebroventricular shunting may be worth investigating further in Alzheimer's disease, according to the authors of a pilot study reported in the Oct. 22 issue of Neurology.
When judging the utility of cerebrospinal fluid biomarkers in Alzheimer disease, it may be less a question of if, but rather when and in whom. In this week’s Journal of Neuroscience, scientists report ...
Research headed by teams at the University of Rochester Center for Translational Medicine and the University of Copenhagen describes for the first time how a spreading wave of disruption and the flow ...